To study the effect of Metronidazole and Ivermectin in hospitalized patients with COVID-19.
Phase 3
- Conditions
- Coronavirus infection.Coronavirus infection, unspecifiedB34.2
- Registration Number
- IRCT20180612040068N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 135
Inclusion Criteria
Hospitalized patient with positive corona test
Exclusion Criteria
Allergic history to Metronidazole or Ivermectin or hypersensitivity reaction to them during trial.
pregnant patients
COPD
Patients suspected to ILD
long history of diabetes
cirrhotic patients
Epileptic patients
patients with sever renal failure ang GFR below 20
participating in another RCT
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main consequences of this trial including; the time of disappearance of shortness of breath, the need for oxygen, the reduction of CRP, the normalization of lymphopenia that will be measured by specialists. Also, the effectiveness of each treatment method will be measured based on the length of hospital stay, the likelihood of hospitalization in the ICU, and the likelihood of mortality. Timepoint: Before starting treatment and at the time of discharge, which should not be less than 5 days. Method of measurement: Blood factors with laboratory methods. Temperature with digital thermometer. Blood pressure with mercury sphygmomanometer or digital pulse oximeter. Other cases with direct observation.
- Secondary Outcome Measures
Name Time Method